Skip to main content
. 2019 Jul 14;11(7):982. doi: 10.3390/cancers11070982

Figure 3.

Figure 3

Combinatorial treatment upregulates expression of SESN2 in human CRC. (A) mRNA expression levels of SESN2 in normal and tumor tissues were evaluated using the mRNA expression data of the IlluminaHiSeq of TCGA CRC. **, p < 0.01. (B) SESN2 protein levels in normal and tumor tissues were evaluated using western blotting. (C,D) Comparison of endogenous expression levels of SESN2 mRNA and protein in normal human cells and human CRC cells using quantitative real-time polymerase chain reaction (qRT-PCR) analysis (C), immunoblotting (D). ***, p < 0.001. (E,F) SESN2 protein levels in the Oxaliplatin and DHA combination was analyzed by immunoblotting (E) and immunofluorescence (F) (Scale bar, 10 μm). (G,H) Following transfection with control small interfering RNA (siRNA) or SESN2 siRNA, cells were exposed to the Oxaliplatin and DHA combination. The mRNA (G) and protein (H) expression of LC3 and p62 were evaluated using qRT-PCR and western blotting. ***, p < 0.001.